Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Phase 1/2a Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KAT-101 in Subjects With HCC

NCT05603572 is registered in ClinicalTrials.gov with Primocure Pharma as lead sponsor.

NCT NCT05603572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05603572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Phase 1/2a Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KAT-101 in Subjects With HCC
Lead sponsor
Primocure Pharma
Phase
Phase 1/2
Overall status
Suspended
Start date
November 1, 2022
Completion date
November 30, 2027
Enrollment
148 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

fibrolamellar carcinoma, hepatocellular carcinoma